Insider trade

Director sold ~$97K of PBYI shares in the open market

Traded Nov 11, 2025 · Filed Nov 14, 2025

Why it stands out

A Puma Biotechnology director sold $97K of Puma Biotechnology shares. The filing does not indicate a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$25K–$100K

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$97,228

Shares × reported transaction price

Timing vs results

5 days after results of Nov 6, 2025, 107 days before results of Feb 26, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.